Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) (EAOC)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland Identifier:
First received: November 18, 2012
Last updated: March 31, 2015
Last verified: March 2015
The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma. All histopathological records since 1980 with these diagnoses (endometriosis, clear cell and endometrioid ovarian carcinoma) will be reviewed. Cancer registry data will be assessed to investigate differences in survival of women with endometriosis-associated ovarian carcinomas and those ovarian carcinoma patients without previous diagnosis of endometriosis.

Endometrioid Carcinoma
Clear Cell Carcinoma

Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) - Epidemiological and Molecular Pathological Aspects

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • incidence and clinical outcome of endometriosis-associated ovarian carcinomas [ Time Frame: 30 years ]

Enrollment: 0
Study Start Date: October 2012
Study Completion Date: December 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care hospital, university hospital

Inclusion Criteria:

  • endometrioid ovarian carcinoma
  • clear cell ovarian carcinoma
  • endometriosis, atypical endometriosis
  • borderline tumors with endometriosis

Exclusion Criteria:

  • undifferentiated carcinomas
  • germ cell tumors
  • sex cord-stromal tumors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01732432

Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Ellen Obermann, MD, Dr. University Hospital Basel, University of Basel
Principal Investigator: Ellen C Obermann, MD Institute of Pathology, University Hospital Basel, University of Basel
  More Information

Responsible Party: University Hospital, Basel, Switzerland Identifier: NCT01732432     History of Changes
Other Study ID Numbers: 210/12
Study First Received: November 18, 2012
Last Updated: March 31, 2015

Additional relevant MeSH terms:
Ovarian Neoplasms
Adenocarcinoma, Clear Cell
Carcinoma, Endometrioid
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Genital Diseases, Female
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms, Complex and Mixed
Endometrial Neoplasms
Uterine Neoplasms processed this record on May 22, 2017